Why Rocket Lab Stock Plummeted 36.1% Last Month But Is Soaring in August

Rocket Lab shares fell 36.1% in July as space-growth valuation de-risking and heightened Iran-related geopolitical risk weighed on the sector. Despite limited negative company-specific news, the stock rallied 27.5% in August after a new U.S. Space Force contract worth up to $397 million (announced Aug. 4) and additional prior-month awards totaling $266 million plus expanded launch agreements. Net effect is mixed: sector-wide risk hurt in July, while contract momentum improved sentiment in August.

Analysis

RKLB’s move should be read less as a revenue story and more as a cost-of-capital story. The market is paying for a higher probability that Neutron becomes a credible government launch platform, which matters because capital-intensive space names only create real equity value once execution reduces dilution risk. Until there is visible hardware progress, though, the stock still trades like a long-duration call option on rates and risk appetite, so factor beta can overwhelm contract wins in the near term.

The main second-order winner is not RKLB’s reported backlog, but its future bargaining power with the Pentagon and other institutional customers: a credible prime relationship can compress future bid friction and improve financing terms. The loser set is the broader basket of space pure-plays that rely on multiple expansion without matching operational proof; SpaceX remains the overhang because any evidence of superior launch economics caps RKLB’s ceiling. The key question is whether this award is a one-off procurement event or the first sign of repeatable programmatic demand.

Consensus may be over-reading the headline as if it de-risks the full equity story. It doesn’t — the real test is first Neutron flight cadence and whether management can translate government validation into margin leverage over the next 6-18 months. Falsifiers are simple: launch delays, slipping test milestones, or any guidance that implies the company must keep funding growth externally at a high rate. If those stay clean, the recent multiple reset looks like a better entry than the July peak.

Key Decisions for Investors

• Buy RKLB only on pullbacks, not into strength; use the current post-announcement rally to wait for a 10-15% retrace or a hold above the breakout zone. 6-12 month setup, with upside driven by Neutron de-risking rather than the contract headline itself.
• If options liquidity allows, use a 3-6 month call spread instead of naked calls to express upside while capping valuation blowoff risk. Best entry is after implied volatility cools from the announcement pop.
• Pair trade: long RKLB / short ARKX as a cleaner idiosyncratic way to isolate RKLB’s government-validation catalyst from the broader space-factor basket. Thesis works if the market keeps rewarding specific execution over thematic exposure.
• Set a hard alert around the next visible Neutron milestone; if testing slips or management guides to heavier external funding, exit the long. That would falsify the thesis that the contract is materially lowering dilution and execution risk.